Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals, Inc. reports developments across a diversified pharmaceutical business built around Affordable Medicines, Specialty and AvKARE. Its updates commonly cover U.S. launches of complex generics, injectables, biosimilars and other affordable medicines, including respiratory inhalation and ophthalmic products, as well as branded specialty treatments in neurology and endocrinology.
News about AMRX also includes clinical and regulatory disclosures for products such as CREXONT for Parkinson’s disease, financial results, capital-structure updates, material agreements and governance matters. AvKARE-related updates center on distribution of pharmaceuticals and medical products to U.S. federal, retail and institutional customers.
Amneal Pharmaceuticals (NYSE: AMRX) has announced the acquisition of Saol Therapeutics' Baclofen franchise, which includes Lioresal and LYVISPAH, for approximately $83.5 million. This move expands Amneal's neurology portfolio and is expected to generate $40-$50 million in annual net revenues by 2025. The acquisition will enhance Amneal's commercial capabilities ahead of its entry into the biosimilar market, with anticipated positive impacts on adjusted EBITDA and earnings per share for 2022.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced that Co-CEO Chirag Patel will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 AM ET. The event will be accessible via a live webcast through the Company’s Investor Relations website, with a replay available for 30 days post-event. Amneal is focused on developing, manufacturing, and distributing generic and specialty pharmaceuticals, with a broad product portfolio across various therapeutic areas. The Company's growth strategy includes expanding its offerings, particularly in injectables and biosimilars.
Amneal Pharmaceuticals (NYSE: AMRX) has received FDA approval for its generic ophthalmic product, difluprednate ophthalmic emulsion 0.05%, a substitute for Durezol®, used to treat pain and inflammation from ocular surgery. This product marks a strategic shift towards more complex offerings in Amneal's portfolio. The annual sales for Durezol® and generics stand at approximately $103 million as of September 2021. However, potential side effects include increased risks of cataracts and glaucoma.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will participate in three upcoming investor conferences. The Jefferies London Healthcare Conference is scheduled for November 18, 2021. The Goldman Sachs Global Sustainability Forum will take place on November 30, 2021. Additionally, Amneal will present at the Evercore ISI 4th Annual HEALTHCONx Virtual Conference on December 1, 2021, with a presentation starting at 8:25 AM Eastern Time. A live webcast will be available on the company's Investor Relations website.
Amneal Pharmaceuticals (NYSE: AMRX) reported Q3 2021 net revenue of $529 million, a 2% increase year-over-year, driven by new generic launches and growth in specialty products like Rytary® and Unithroid®. The company posted a net loss of $(4) million compared to $(9) million in Q3 2020, reflecting improved gross margins and decreased impairment charges. Adjusted EBITDA rose to $135 million, up 19% from last year. Amneal also announced the acquisition of Puniska Healthcare for $93 million, enhancing its injectables capabilities and expanding market reach.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has released its inaugural Corporate Responsibility Report, showcasing its commitment to environmental, social, and governance (ESG) practices with data primarily from 2020 and highlights from 2021. The report details Amneal's focus on five key impact areas: people, products, governance, planet, and community, including its role in combating COVID-19. The company emphasizes its ongoing dedication to enhancing employee diversity, R&D for affordable medications, and supporting social advocacy.
Amneal Pharmaceuticals (NYSE: AMRX) has announced the launch of dexamethasone in 4mg and 6mg formulations following FDA approval. This glucocorticoid steroid is crucial for treating various conditions, including COVID-19 complications. The U.S. market for these dexamethasone tablets reached approximately $63 million in annual sales as of August 2021. The company emphasizes its commitment to expanding access to essential therapies while recognizing potential risks, including HPA axis suppression and contraindications for allergic patients.
Amneal Pharmaceuticals (NYSE: AMRX) will release its Q3 2021 financial results on November 3, 2021, before market open. A conference call and live webcast will follow at 8:30 a.m. ET on the same day. Investors can access the results and webcast via the Investor Relations section of the company's website. Callers in the U.S. can reach the conference at (844) 200-6205, while international callers can dial (929) 526-1599. A replay will be available for seven days using access code 781882.
Amneal Pharmaceuticals (NYSE: AMRX) announced its participation in the Morgan Stanley Global Healthcare Conference on September 15, 2021, at 1:15 PM ET. Investors can access the live webcast through the company's Investor Relations page, with a replay available for 90 days afterward. Amneal is a fully-integrated pharmaceutical company based in Bridgewater, NJ, focusing on generic and specialty drug products, with a portfolio of approximately 250 product families.
Amneal Pharmaceuticals (NYSE: AMRX) announced positive topline results from its pivotal Phase 3 RISE-PD clinical trial for IPX-203, a novel formulation for Parkinson’s disease. The trial met its primary endpoint, showing an increase of 0.53 hours in “Good On” time compared to immediate-release CD/LD (p=0.0194). A New Drug Application submission to the FDA is planned for mid-2022. The trial involved 506 patients across 108 sites, demonstrating the drug's efficacy and safety, with 29.7% of patients reporting significant improvements (p=0.0015).